Search results for "VITA"

showing 10 items of 3155 documents

Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy

1995

OBJECTIVE To determine whether lipoic acid (LA) will reduce oxidative stress in diabetic peripheral nerves and improve neuropathy. RESEARCH DESIGN AND METHODS We used the model of streptozotocin-induced diabetic neuropathy (SDN) and evaluated the efficacy of LA supplementation in improving nerve blood flow (NBF), electrophysiology, and indexes of oxidative stress in peripheral nerves affected by SDN, at 1 month after onset of diabetes and in age-matched control rats. LA, in doses of 20, 50, and 100 mg/kg, was administered intraperitoneally five times per week after onset of diabetes. RESULTS NBF in SDN was reduced by 50% LA did not affect the NBF of normal nerves but improved that of SDN i…

medicine.medical_specialtyTime FactorsDiabetic neuropathyEndocrinology Diabetes and MetabolismNeural Conductionmedicine.disease_causeNerve conduction velocityDiabetes Mellitus Experimentalchemistry.chemical_compoundDiabetic NeuropathiesGanglia SpinalDiabetes mellitusInternal medicineWeight LossInternal MedicinemedicineAnimalsHumansVitamin EAdvanced and Specialized NursingThioctic AcidVitamin A Deficiencybusiness.industryGlutathionemedicine.diseaseGlutathioneSciatic NerveRatsOxidative StressLipoic acidPeripheral neuropathyEndocrinologychemistryRegional Blood FlowSciatic nervebusinessOxidative stressDiabetes Care
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct

Safety of agalsidase alfa in patients with Fabry disease under 7 years

2011

Aim:  To evaluate the safety and explore the efficacy of enzyme replacement therapy (ERT) for Fabry disease with agalsidase alfa in young children enrolled in the Fabry Outcome Survey (FOS). Methods:  This retrospective chart review identified eight children (mean age = 5.0 ± 1.6 [mean ± SD]) in FOS who began treatment with agalsidase alfa (0.2 mg/kg, i.v., every other week) when <7 years old. Vital signs and adverse events were monitored throughout the study period. Glomerular filtration rate (GFR) was estimated, and left ventricular mass indexed to height2.7 (LVMi) was assessed with echocardiography. Patients received 1.2–6.7 years of treatment (mean = 4.2 years). Results:  Infusion react…

medicine.medical_specialtyVascular diseasebusiness.industryOrgan dysfunctionVital signsRenal functionRetrospective cohort studyGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryInternal medicinePediatrics Perinatology and Child Healthmedicinemedicine.symptomAdverse effectbusinessActa Paediatrica
researchProduct

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms

2001

To induce atherogenesis in mice, a high fat (HF) diet is supplemented with cholic acid (CA), which increases apoB-containing particles and lower apoA-I-containing particles. HF diet without CA increases levels of both HDL and LDL, suggesting that CA may be responsible for the elevation of LDL and lowering of HDL. The mechanism of dietary CA-induced lowering of apoA-I-containing particles has recently been reported. In this study, we examined the mechanism of CA- and HF-induced elevation of apoB-containing lipoproteins in mice. Mice were fed the following four diets: control chow (C), high fat high cholesterol, (HF), control and 0.5% cholate (CA), and HF + CA. Dietary CA increased the plasma…

medicine.medical_specialtyVery low-density lipoproteinSettore MED/09 - Medicina InternaMouseApolipoprotein Bmedicine.medical_treatmentDown-RegulationCholic AcidLipoproteins VLDLBiochemistryDietary cholateMicechemistry.chemical_compoundApolipoproteins ERibonucleasesDownregulation and upregulationInternal medicinemedicineAnimalsVitamin ERNA MessengerRNA Processing Post-TranscriptionalReceptorApolipoproteins BbiologyChemistryVitamin ECholic acidnutritional and metabolic diseasesCell BiologyBlotting NorthernDietLipoproteins LDLMice Inbred C57BLCholesterolEndocrinologyLiverReceptors LDLLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Gene expressionHepatic lipaseApolipoprotein BCholatesDietary fatThe International Journal of Biochemistry &amp; Cell Biology
researchProduct

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.

2011

Purpose: This study evaluated the safety and effectiveness of long-term enzyme replacement therapy with idursulfase (recombinant human iduronate-2-sulfatase) in patients with Hunter syndrome. Methods: All 94 patients who completed a 53-week double-blinded study of idursulfase enrolled in this open-labeled extension study and received intravenous idursulfase at a dose of 0.5 mg/kg weekly for 2 years, and clinical outcomes and safety were assessed. Results: No change in percent predicted forced vital capacity was seen, but absolute forced vital capacity demonstrated sustained improvement and was increased 25.1% at the end of the study. Statistically significant increases in 6-minute walking t…

medicine.medical_specialtyVital capacityAdolescentIdursulfaseIduronate SulfatasePulmonary function testingInternal medicineMedicineHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIAdverse effectChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IIbusiness.industryPercent Predicted Forced Vital CapacityHunter syndromeEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryTreatment OutcomeLiverChild PreschoolbusinessSpleenmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Objectifying acupuncture effects by lung function and numeric rating scale in patients undergoing heart surgery.

2012

Rationale. Poststernotomy pain and impaired breathing are common clinical problems in early postoperative care following heart surgery. Insufficiently treated pain increases the risk of pulmonary complications. High-dose opioids are used for pain management, but they may cause side effects such as respiratory depression.Study Design. We performed a prospective, randomized, controlled, observer-blinded, three-armed clinical trial with 100 patients. Group 1 (n=33) and Group 2 (n=34) received one 20 min session of standardized acupuncture treatment with two different sets of acupoints. Group 3 (n=33) served as standard analgesia control without additional intervention. Results. Primary endpoin…

medicine.medical_specialtyVital capacityArticle Subjectbusiness.industryAnalgesiclcsh:Other systems of medicinelcsh:RZ201-999Pulmonary function testingSurgeryClinical trialFEV1/FVC ratioComplementary and alternative medicineStatistical significanceAcupuncturemedicineClinical endpointbusinessResearch ArticleEvidence-based complementary and alternative medicine : eCAM
researchProduct

Abdominal wall incisional hernia repair improves respiratory function: results after 3 years of follow-up

2020

Abstract Purpose Hernias severely impact patient quality of life (QoL), and 80% of patients require a surgical operation. Moreover, hernias are responsible for respiratory function alterations. This study aims to investigate the postoperative alterations in respiratory function after open ventral hernia repair in patients with incisional hernia. Methods Patients operated on at the Policlinico “Paolo Giaccone” at Palermo University Hospital between January 2015 and December 2016 were identified in a prospective database. Fifty-one patients were enrolled in the study. The respiratory outcome measures used were forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio…

medicine.medical_specialtyVital capacityIncisional herniaVentral hernia repairAbdominal wallFEV1/FVC ratioQuality of lifemedicineHumansRespiratory functionRespiratory systemRespiratory outcomeIncisional herniaHerniorrhaphybusiness.industryAbdominal Wallrespiratory systemmedicine.diseaseHernia Ventralrespiratory tract diseasesSurgerymedicine.anatomical_structureQuality of LifeOriginal ArticleSurgerybusinesscirculatory and respiratory physiologyFollow-Up StudiesAbdominal surgery
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct

Inspiratory and Lower-Limb Strength Importance in Mountain Ultramarathon Running. Sex Differences and Relationship with Performance

2020

The study was aimed at comparing lower-limb strength and respiratory parameters between male and female athletes and their interaction with performance in a 107 km mountain ultramarathon. Forty seven runners (29 males and 18 females

medicine.medical_specialtyVital capacityPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseankle reactive strengthArticleLower limbultraendurancePulmonary function testinglcsh:GV557-1198.99503 medical and health sciences0302 clinical medicineInternal medicinemedicineisometric strengthOrthopedics and Sports MedicineRespiratory systemlcsh:SportsbiologyAthletesbusiness.industrypulmonary functionInspiratory muscle030229 sport sciencesbiology.organism_classificationmedicine.anatomical_structureCardiologyventilatory efficiencyAnklebusinesshuman activities030217 neurology & neurosurgerySports
researchProduct

SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS

2019

Copyright © 2019 Pinto and de Carvalho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

medicine.medical_specialtyVital capacityPrognostic variableamyotrophic lateral sclerosisNeurologyNeurologipredictorlcsh:RC346-429functional outcome03 medical and health sciencesFEV1/FVC ratioslow vital capacity0302 clinical medicineInternal medicinemedicineRespiratory function030212 general & internal medicineAmyotrophic lateral sclerosisRespiratory systemlcsh:Neurology. Diseases of the nervous systembusiness.industryProportional hazards modelNeurosciencesBrief Research Reportmedicine.diseaseNeurologyCardiologyrate of progressionNeurology (clinical)business030217 neurology & neurosurgeryNeurovetenskaperFrontiers in Neurology
researchProduct